239 related articles for article (PubMed ID: 18478776)
1. [Monoclonal gammapathy of undetermined significance and autoimmune disease: description of three cases in Senegal].
Diallo S; Ndiaye FS; Pouye A; Lèye A; Touré MA; Diop S; Dièye T; Ka MM; Thiam D; Diakhaté L; Diop TM
Med Trop (Mars); 2008 Feb; 68(1):65-8. PubMed ID: 18478776
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein.
Anagnostopoulos A; Galani E; Gika D; Sotou D; Evangelopoulou A; Dimopoulos MA
Ann Hematol; 2004 Oct; 83(10):658-60. PubMed ID: 15278296
[TBL] [Abstract][Full Text] [Related]
3. [Laboratory diagnosis of monoclonal gammopathies. Prospective study of 14 cases in Dakar, Senegal].
Diop PA; Haudrechy D; Sylla-Niang M; Diedhiou A; Ngom L; Lopez-Sall P
Bull Soc Pathol Exot; 1998; 91(3):242-6. PubMed ID: 9773201
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
5. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal gammopathy of undetermined significance].
Chaïbi P; Merlin L; Thomas C; Piette F
Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases].
Mseddi-Hdiji S; Haddouk S; Ben Ayed M; Tahri N; Elloumi M; Baklouti S; Hachicha J; Krichen MS; Bahloul Z; Masmoudi H
Pathol Biol (Paris); 2005 Feb; 53(1):19-25. PubMed ID: 15620605
[TBL] [Abstract][Full Text] [Related]
8. [Study of monoclonal gammopathy in Kagawa Prefectural Central Hospital].
Uchida M; Taida N; Kanao M; Kagamihara H; Kuwajima M
Rinsho Byori; 2004 Jul; 52(7):574-9. PubMed ID: 15344556
[TBL] [Abstract][Full Text] [Related]
9. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal gammopathy in a tertiary referral hospital.
Tamimi W; Alaskar A; Alassiri M; Alsaeed W; Alarifi SA; Alenzi FQ; Jawdat D
Clin Biochem; 2010 Jun; 43(9):709-13. PubMed ID: 20206156
[TBL] [Abstract][Full Text] [Related]
11. [Incidence, clinico-biological characteristics, and clinical course of 1,203 monoclonal gammopathies (1971-1992)].
Giraldo P; Rubio-Félix D; Cortés T; Delgado P; Franco E; Gimeno J; Tapia M; Giralt M
Sangre (Barc); 1994 Oct; 39(5):343-50. PubMed ID: 7754438
[TBL] [Abstract][Full Text] [Related]
12. Presence of crystalline inclusions in the peripheral nerve of a patient with IgA lambda monoclonal gammopathy of undetermined significance.
Vital A; Nedelec-Ciceri C; Vital C
Neuropathology; 2008 Oct; 28(5):526-31. PubMed ID: 18410274
[TBL] [Abstract][Full Text] [Related]
13. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F; Petrucci MT; Guffanti A; Marcheselli L; Rossi D; Callea V; Vincenzo F; De Muro M; Baraldi A; Villani O; Musto P; Bacigalupo A; Gaidano G; Avvisati G; Goldaniga M; Depaoli L; Baldini L
Clin Cancer Res; 2009 Jul; 15(13):4439-45. PubMed ID: 19509142
[TBL] [Abstract][Full Text] [Related]
14. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Mellemkjaer L; Ibsen JS; Dahlerup JF; Thomassen L; Sørensen HT
Haematologica; 2001 Nov; 86(11):1172-9. PubMed ID: 11694403
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal gammopathies in a series of 1683 plasma donors].
Tichý M; Rehácek V; Maisnar V; Dominiková K; Palicka V
Cas Lek Cesk; 2004; 143(6):401-4; discussion 404. PubMed ID: 15309868
[TBL] [Abstract][Full Text] [Related]
16. [Acquired peripheral neuropathies associated with monoclonal gammopathy].
Gajos A; Kieliś W; Szadkowska I; Chmielowska E; Niewodniczy A; Bogucki A
Neurol Neurochir Pol; 2007; 41(2):169-75. PubMed ID: 17530580
[TBL] [Abstract][Full Text] [Related]
17. Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance.
Kelly JJ
Rev Neurol Dis; 2008; 5(1):14-22. PubMed ID: 18418318
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.
Eisele L; Dürig J; Hüttmann A; Dührsen U; Assert R; Bokhof B; Erbel R; Mann K; Jöckel KH; Moebus S;
Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623
[TBL] [Abstract][Full Text] [Related]
19. [Nosology and management of monoclonal gammapathy].
Grosbois B; Decaux O; Guenet L; Goasguen J; Jego P
Bull Acad Natl Med; 2009 May; 193(5):1069-85; discussion 1085-7. PubMed ID: 20120388
[TBL] [Abstract][Full Text] [Related]
20. Papuloerythroderma associated with monoclonal gammopathy of undetermined significance.
Fujimura T; Okuyama R; Ogawa E; Aiba S
J Dermatol; 2009 Apr; 36(4):228-31. PubMed ID: 19348662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
